Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations

Clin Infect Dis. 2019 Jan 18;68(3):519-524. doi: 10.1093/cid/ciy576.


Ceftazidime/avibactam and meropenem/vaborbactam are changing the management of invasive infections due to carbapenem-resistant Enterobacteriaceae (CRE), leading to higher rates of clinical cure, decreased mortality, and decreased rates of acute kidney injury compared with colistin-based regimens. However, these 2 agents are not interchangeable with regard to management of CRE infections, and clinicians need to be aware of their differences. This review focuses on differences in the in vitro activity of these agents as a function of mechanism of carbapenem resistance, the clinical data supporting their superiority over colistin-based therapy, and the differences between agents with regard to propensity for selection of resistance. Furthermore, considerations and recommendations for hospital formularies and antibiotic stewardship programs regarding positioning of these agents are discussed.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azabicyclo Compounds / therapeutic use*
  • Boronic Acids / therapeutic use*
  • Carbapenem-Resistant Enterobacteriaceae / drug effects*
  • Carbapenem-Resistant Enterobacteriaceae / isolation & purification
  • Ceftazidime / therapeutic use*
  • Disease Management*
  • Drug Combinations
  • Enterobacteriaceae Infections / drug therapy*
  • Enterobacteriaceae Infections / microbiology
  • Heterocyclic Compounds, 1-Ring / therapeutic use*
  • Humans
  • Meropenem / therapeutic use*
  • beta-Lactamase Inhibitors / therapeutic use*


  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Boronic Acids
  • Drug Combinations
  • Heterocyclic Compounds, 1-Ring
  • avibactam, ceftazidime drug combination
  • beta-Lactamase Inhibitors
  • meropenem and vaborbactam
  • Ceftazidime
  • Meropenem